6-氟-1-(4-氟苯基)-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸 | 100490-21-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 中文名称: 6-氟-1-(4-氟苯基)-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸
• 英文名称: sarafloxacin
• 英文别名: A 57132；1-p-fluorophenyl-6-fluoro-1,4-dihydro-4-oxo-7(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid；6-Fluoro-1-(4-fluorophenyl)-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid；6-fluoro-1-(4-fluorophenyl)-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid
• CAS: 100490-21-9
• 化学式: C₁₉H₁₆F₂N₄O₃
• 分子量: 386.358
• InChiKey: ROMLGDPRVIVYSV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  28
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.21
• 拓扑面积：
  85.8
• 氢给体数：
  2
• 氢受体数：
  9

反应信息

• 作为产物：
  描述：

  Ethyl 7-(4-acetylpiperazin-1-yl)-6-fluoro-1-(4-fluorophenyl)-4-oxo-1,8-naphthyridine-3-carboxylate 生成 6-氟-1-(4-氟苯基)-4-氧代-7-(哌嗪-1-基)-1,4-二氢-1,8-萘啶-3-羧酸
  参考文献：
  名称：

  NARITA, XIROKADZU;KONISI, JOSINORI;NITTA, DZYUN;NAGAKI, XIDEHESI;KITAYAMA+

  摘要：

  DOI：

文献信息

• Naphthyridine antibacterial compounds
  申请人：Abbott Laboratories

  公开号：US04616019A1

  公开（公告）日：1986-10-07

  Naphthyridine compounds having the formula: ##STR1## wherein Z is an amine or an aliphatic heterocyclic group, R is a phenyl group or an aromatic heterocyclic group and R.sub.1 is hydrogen or a carboxy protecting group. The compounds of the invention have antibacterial activity.

  具有以下式子的萘啶化合物：##STR1## 其中Z是胺基或脂肪族杂环基，R是苯基或芳香族杂环基，R.sub.1是氢或羧基保护基。本发明的化合物具有抗菌活性。
• Controlled porosity osmotic pump
  申请人：Merck & Co., Inc.

  公开号：EP0169105A2

  公开（公告）日：1986-01-22

  (57) The instant invention is directed to an osmotic pump comprising: (a) at least one active agent surrounded by (b) a water insoluble wall, having a fluid permeability of 6.96 x 10-18 to 6.96 x 10-14cm3 sec/g and a reflection coefficient of less than 1, prepared from: (i) a polymer permeable to water but impermeable to solute, and (ii) 0.1 to 60% by weight, based on the total weight of (i) and (ii), of at least one pH insensitive pore forming additive dispersed throughout said wall.

  (57) 本发明涉及一种渗透泵，包括：(a)至少一种活性剂，由(b)不溶于水的壁包围，其流体渗透性为6.96×10-18至6. 96 x 10-14cm3 sec/g，反射系数小于 1，由以下材料制备：(i)可渗透水但不渗透溶质的聚合物，和(ii)以(i)和(ii)的总重量为基准，按重量计为 0.1 至 60%，分散在所述壁中的至少一种对 pH 值不敏感的形成孔隙的添加剂。
• Controlled drug device and process for catalysing the erosion of an acid labile polymer
  申请人：Merck & Co., Inc.

  公开号：EP0208617A1

  公开（公告）日：1987-01-14

  The invention relates to the use of carboxylic, sulfonic, phosphatidic and/or phosphate ester acids incorporated as a catalyst in poly(ortho­ester)s and other acid labile polymers such that upon exposure to aqueous environments the acid catalyzes the erosion of the polymer matrix. The rate of release of a drug substance incorporated into or surrounded by the poly(orthoester) or other acid labile polymer can be controlled in that the drug is released as the polymer is eroded in response to the catalytic action of the acid incorporated therein.

  本发明涉及使用羧酸、磺酸、磷脂酸和/或磷酸酯酸作为催化剂加入聚（邻苯二甲酸酯）和其他酸性聚合物中，使其在暴露于水性环境时催化聚合物基质的侵蚀。掺入聚（邻苯二甲酸酯）或其他酸性聚合物中或被其包围的药物物质的释放速度可以得到控制，因为在掺入其中的酸的催化作用下，当聚合物被侵蚀时，药物就会释放出来。
• Hydrostatic delivery system for controlled delivery of agent
  申请人：——

  公开号：US20020155067A1

  公开（公告）日：2002-10-24

  The present invention provides a hydrostatic delivery system comprising a hydrostatic couple and an agent of interest. The hydrostatic couple comprises, at least one hydrodynamic fluid-imbibing polymer, and at least one hydrostatic pressure modulating agent. This delivery system has the ability to control the release of one or more agent of interest within a fluid environment following zero-order kinetics.

  本发明提供了一种由静水耦合剂和相关药剂组成的静水给药系统。流体静力学耦合剂包括至少一种流体静力学流体粘附聚合物和至少一种流体静力学压力调节剂。这种给药系统能够在流体环境中按照零阶动力学控制一种或多种相关药剂的释放。
• NARITA, XIROKADZU;KONISI, JOSINORI;NITTA, DZYUN;NAGAKI, XIDEHESI;KITAYAMA+
  作者：NARITA, XIROKADZU、KONISI, JOSINORI、NITTA, DZYUN、NAGAKI, XIDEHESI、KITAYAMA+

  DOI：——

  日期：——